SylamoreBio Partners with Daiichi Sankyo to Advance CNS Therapeutics
Biotech Pioneer SylamoreBio Collaborates with Daiichi Sankyo to Tackle CNS Delivery Challenges How can biotech companies overcome the formidable barriers to delivering therapies to the central nervous system (CNS)? SylamoreBio,…
Blackstone Life Sciences Advances AML Treatment With Bleximenib Funding
BXLS and Johnson & Johnson Collaborate to Fund Bleximenib Clinical Trials for AML Why is the development of new treatments for acute myeloid leukemia (AML) so critical? Despite being the…
Bristol Myers Squibb Advances Alpha-Thalassemia Treatment With Reblozyl
Positive Top-Line Results for Reblozyl in Alpha-Thalassemia Study Is the treatment landscape for alpha-thalassemia about to change? Bristol Myers Squibb has announced positive top-line results from an ongoing, ex-US, Phase…
Merck Reorganizes Human Health Business to Drive Commercial Success
Merck Evolves Structure to Enhance Commercial Execution and Portfolio Growth In an industry where the pace of innovation and market dynamics are constantly evolving, how can pharmaceutical companies ensure they…
Gilead Sciences Acquires Arcellx for $7.8 Billion to Advance Cancer Immunotherapies
Gilead Sciences Seals $7.8 Billion Deal for Arcellx to Boost CAR T-Cell Therapy In the rapidly evolving landscape of cancer immunotherapies, where breakthroughs are crucial for patient outcomes, Gilead Sciences,…
AOP Health Advances Rare Disease Care With Collaborative Data and Patient Engagement
AOP Health Emphasizes Collaboration and Patient-Centered Information on Rare Disease Day 2026 Why is the diagnosis and treatment of rare diseases so challenging? AOP Health, a global enterprise group with…
Savara Reports FDA Filing of BLA for MOLBREEVI in Autoimmune Pulmonary Alveolar Proteinosis
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Savara Inc. a clinical-stage biopharmaceutical company focused…
Science Corp. Partners with Neurosoft Bioelectronics to Advance Next-Generation BCI Ecosystem
Science Corp. and Neurosoft Bioelectronics Announce Novel BCI Ecosystem Partnership Science Corporation, the pioneering full-stack neural engineering company focused on restoring and extending life, and Neurosoft Bioelectronics, a neural data company…
Dr. Reddy’s Secures FDA Review of Biologics License Application for Abatacept Biosimilar
Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept Dr. Reddy’s Laboratories Ltd. along with its subsidiaries together referred to as “Dr.…
FDA Approves CALQUENCE® and Venetoclax as First Fixed-Duration, All-Oral Regimen for Frontline CLL
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting AstraZeneca’sCALQUENCE® in combination with venetoclax has been approved…
Seaport Therapeutics Shares Meta-Analysis Highlighting Trial Design Effects on Placebo Response in GAD
Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials Seaport Therapeutics a clinical-stage therapeutics company advancing novel neuropsychiatric…
FDA Accepts Genentech’s NDA for Giredestrant in ESR1-Mutated Advanced Breast Cancer
FDA Accepts New Drug Application for Genentech’s Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer Genentech, a member of the Roche Group announced today that the U.S. Food and Drug Administration…